Ezetimibe--a new cholesterol-lowering drug.
Use of statin therapy is a key first-line approach in preventing coronary heart disease events and stroke in people at increased risk of developing such complications. Ezetimibe (Ezetrol - MSD-Schering-Plough), the first licensed azetidinone drug, is being promoted as an adjunct to statin therapy to achieve greater reductions in blood cholesterol concentrations than occur with a statin alone. Here we review ezetimibe and consider its place in clinical practice.
D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D001384:Azetidines / Q000191:economics / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D016527:Drug Costs; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D000069438:Ezetimibe